Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06065046
PHASE2

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Sponsor: Tang-Du Hospital

View on ClinicalTrials.gov

Summary

The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.

Official title: A Randomized Control Trial of Baricitinib Administration in Patients With Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2023-11-24

Completion Date

2026-12-31

Last Updated

2025-06-04

Healthy Volunteers

No

Interventions

DRUG

Baricitinib 4 MG

Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days

OTHER

Standard treatment

Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.

Locations (1)

Tandu Hospital, Fourth Military Medical University

Xi'an, Shaanxi, China